
# Dr. Sanjay Singh

#### CURRENTLY

Chief Executive Officer and Executive Director Gennova Biopharmaceuticals Ltd, Pune, India

#### **Responsibilities**

 Central Drugs Standard Control Organization (CDSCO), Drug Controller General of India (DCGI), Ministry of Health, Govt. of India for development of the India Guidelines on Similar Biologics (Regulatory Requirements for Marketing Authorization).



- Working group for Gene Therapy constituted jointly by the Department of Health Research (DHR) and Department of Biotechnology (DBT), Govt. of India.
- Indo-US Vaccine Action Programme (VAP), Invited Member.
- Member of the Scientific Advisory Board of the National Center for Cell Sciences (NCCS).

# **CAREER TIMELINE**

2006 — present	CEO, Gennova Biopharmaceuticals Ltd., Pune, India.
2003 - 2006	Head, Antigen Research Section at National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
2000 - 2003	Senior Staff Scientist at National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
1996 — 2000	Research Scientist at International Center for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India

### HONORS AND AWARDS

- US Department of Human and Health Services
- 2005-Special Act or Service Award
- 2004-Staff Recognition Award, NIAID/NIH



• Ph.D. in Biochemistry from the Central Drug Research Institute (CDRI), Lucknow, India.

## **CAREER HIGHLIGHTS**

- During his tenure at the NIH, Dr. Singh was successful in taking four recombinant vaccine candidates from gene to Phase I human clinical trials.
- At Gennova, Dr. Singh's leadership has facilitated the launch of Elaxim<sup>™</sup> (TNK-tPA for AMI); Tenectase<sup>™</sup> (TNK-tPA for AIS); Vintor<sup>™</sup> (Erythropoietin); Emgrast<sup>™</sup> (Sargramostim); Exgrast<sup>™</sup> (Filgrastim); PEGEX<sup>™</sup> (Pegylated filgrastim) and Hamsyl<sup>®</sup>(Pegaspargase) in the market.
- Key role in development of transmission blocking vaccine for Malaria under REDMAL -Seventh Framework Program (FP7) for Research and Technological Development of the European Committee for elimination and eventual eradication of Malaria.
- His scientific acumen lead to the approval of Tenecteplase for Acute Ischemic Stroke (AIS), -First time in the World.
  - This innovation was recognized by the Department of Biotechnology (DBT), Govt. of India for the 'Biotech product, process development and commercialization award 2019'.
  - Additionally, this 'Make in India' product has found its way in the list of drugs for emergency care for stroke management in the guideline –'Prevention and Management of Stroke', issued by the Ministry of Health and Family Welfare, Govt. of India.

### **SELECTED PUBLICATIONS**

- NPJ Vaccines. 2018 Sep 28;3:48. doi: 10.1038/s41541-018-0083-3
- NPJ Vaccines 2017 2:10 ; doi:10.1038/s41541-017-0011-y
- PLoS Clin Trials, 2007, 2(4):e12.
- Infection & Immunity, Jul 2005, 73(7):3963-70.
- Journal of Biological Chemistry, 2001, 276 (20): 171 11.

### **SELECTED PATENTS**

- Pharmaceutical Composition of Tenecteplase (TNK-tPA), 2018 (US9943575B2)
- Pharmaceutical Composition of Tenecteplase (TNK-tPA), , 2010 (PCT/IN2011/000863)
- A Noval Process for Purification of rHu-GCSF, 2015 (PCT/IN2015/050066)
- A Novel Purification Process for Isolation and Commercial Production of Recombinant TNKtPA (PCT/IN2015/050137)

